To amend title 49, United States Code, to extend the non-premium war risk insurance program.

HR4762, despite its misleading title on Congress.gov, is a bill to prohibit the export of specific drugs and prosthetics to the Russian Federation. The actual text, titled the "Medical Supply Sanctions Act of 2025," mandates the President to ban the export of drugs approved under sections 505 of the Federal Food, Drug, and Cosmetic Act or 351 of the Public Health Service Act, and FDA-authorized prosthetics. This sanction remains in effect until the Secretary of State certifies Russia has ceased military operations in Ukraine and withdrawn its forces. This action immediately reduces the market access for U.S. pharmaceutical and medical device companies for these specific products in Russia. There is no direct funding mechanism or appropriation associated with this bill. Instead, it creates a regulatory barrier, effectively closing off the Russian market for certain U.S.-manufactured drugs and prosthetics. Companies that previously exported these items to Russia will lose that revenue stream. The impact is a reduction in the total addressable market for these specific products, forcing companies to reallocate resources or focus on other markets. The money trail is negative, representing lost sales rather than new opportunities. Historically, sanctions on specific goods have led to market adjustments for affected companies. For example, following the initial broad sanctions against Russia in 2014, many companies adjusted their international sales strategies. While not directly comparable to a specific medical export ban, broader sanctions on technology and energy sectors have shown that companies with significant exposure to sanctioned countries experience revenue declines. The current bill is more targeted, focusing on specific medical products. The impact will be felt by companies that have maintained a presence in Russia for these products, even after earlier, broader sanctions. Specific companies that stand to lose include major pharmaceutical companies with drug approvals that would fall under this definition, such as Johnson & Johnson ($JNJ), Pfizer ($PFE), and Merck & Co. ($MRK). Medical device manufacturers producing FDA-authorized prosthetics, like Abbott Laboratories ($ABT), Stryker Corporation ($SYK), and Zimmer Biomet Holdings ($ZBH), will also see their Russian market access eliminated for these products. The bill is currently in the House and has been referred to the Committee on Foreign Affairs. Its placement on the Union Calendar indicates it is ready for floor consideration, suggesting a relatively swift path forward if it gains traction. The next step is a vote in the House, followed by Senate consideration if passed. This bill is sponsored by Rep. Luttrell, a Republican. While not a committee chair, the sponsorship indicates a clear legislative intent to further sanction Russia, aligning with broader U.S. foreign policy objectives regarding the conflict in Ukraine. The bill's specific focus on medical supplies, which are often exempted from broader sanctions for humanitarian reasons, signifies a hardening stance.